BioCentury
ARTICLE | Finance

Medigene remade

How Medigene found new investors by focusing exclusively on immunotherapy

August 17, 2015 7:00 AM UTC

Within 18 months, Medigene AG has used a small acquisition to gain a new, predominantly institutional shareholder base that has infused the German company with enough cash to pursue three platforms in parallel.

Management says the key to courting the new investors, most of which are based in the U.S. and in European countries outside Germany, was morphing into a pure-play biotech focused on cancer immunotherapy...